The doxorubicin analogon DA-125 could reduce proliferation in HT1080 fibrosarcoma cells through a NFKB dependent pathway [29] and recent studies showed that tumor invasiveness could be significantly reduced by inhibiting NFKB activity [30], pointing to this transcription factor as a key element in HT1080 proliferation-pathways. The gene discussed is NFKB1; the disease is neoplasm.